News ESC26: Cytokinetics' big data reveal for Myqorzo impresses Cytokinetics has revealed highly anticipated data from the ACACIA-HCM study of Myqorzo in non-obstructive hypertrophic cardiomyopathy at ESC 2026.
News Cytokinetics' cardiomyopathy drug cleared for NHS use Cytokinetics gets simultaneous MHRA and NICE approvals for hypertrophic cardiomyopathy (HCM) therapy Myqorzo.
News After rival fails, Cytokinetics could broaden Myqorzo label Cytokinetics' Myqorzo has succeeded where BMS's first-to-market Camzyos failed, with a positive trial in non-obstructive hypertrophic cardiomyopathy.
News GSK showcases positive data with lung cancer drugs at WCLC New data at WCLC26 could push GSK's ROS1+ NSCLC drug Jideytro into the first-line setting, while B7-H3-targeted ADC ris-rez extends survival in SCLC.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.